Akero Therapeutics, Inc.

Ownership Transactions Reported by 17 Insiders

Symbol
AKRO on Nasdaq
Location
601 Gateway Boulevard, Suite 350, South San Francisco, CA

Insiders trading volume in the past year

Akero Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
G. Walmsley Graham Director $48.1M +$9.6M +24.9% Jan 30, 2025
Andrew Cheng President and CEO, Director $38.3M -$13.3M -25.8% Feb 10, 2025
Jonathan Young Chief Operating Officer $23.4M -$5.1M -17.9% Feb 3, 2025
Timothy Rolph Chief Scientific Officer $9.69M -$3.16M -24.6% Feb 5, 2025
Catriona Yale Chief Development Officer $5.45M -$9.62M -63.8% Jan 27, 2025
Skorpios Trust Former 10% owner $2.01M Dec 1, 2022
William Richard White Chief Financial Officer $1.95M -$8.2M -80.8% Dec 16, 2024
Patrick Lamy Senior VP, Commercial Strategy $1.91M -$356K -15.7% Dec 31, 2024
Scott A. Gangloff Chief Technology Officer $756K Dec 16, 2024
ATP Life Science Ventures, L.P. 10%+ Owner Jun 28, 2021
Chou Judy Director Jun 8, 2024
Kevin Bitterman Director Jun 1, 2021
Jane Henderson Director Jun 8, 2024
Tomas J. Heyman Director Jun 8, 2024
Seth Loring Harrison Director Jun 8, 2024
Yuan Xu Director Jun 8, 2024
Mark Iwicki Director Jun 8, 2024

Recent Insider Transactions by Companies or Individuals for Akero Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.